Human 4-1BB Ligand/TNFSF9 Antibody Summary
Accession # P41273
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human 4‑1BB Ligand/TNFSF9 by Western Blot. Western blot shows lysates of human placenta tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human 4-1BB Ligand/TNFSF9 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2295) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF017). A specific band was detected for 4-1BB Ligand/TNFSF9 at approximately 26 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
4‑1BB Ligand/TNFSF9 in Human Placenta. 4-1BB Ligand/TNFSF9 was detected in immersion fixed paraffin-embedded sections of human placenta using Goat Anti-Human 4-1BB Ligand/TNFSF9 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2295) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to syncytiotrophoblasts. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: 4-1BB Ligand/TNFSF9
4-1BB ligand (4-1BBL; also CD137L) is a 32 kDa type II transmembrane protein that belongs to the TNF superfamily (TNFSF) molecules (1‑4). The human 4-1BBL cDNA encodes a 254 amino acid (aa) protein that contains a 25 aa N-terminal cytoplasmic domain, a 23 aa transmembrane segment, and a 206 aa C-terminal extracellular region (5). The extracellular domain (ECD) of 4-1BBL has a jelly-roll, beta -sandwich tertiary structure that is similar to other TNFSF members. There is only one cysteine in the human ECD, and no potential N-linked glycosylation sites. The potential exists, however, for O-linked glycosylation. The human 4-1BBL ECD shares 32% and 35% aa identity with mouse and rat ECD, respectively. In the cytoplasmic domain, human 4-1BBL is 55 aa shorter than the equivalent region in rodents. 4-1BBL is expressed by activated B cells, macrophages, dendritic cells, activated T cells, neurons and astrocytes (2, 3, 6). A 26 kDa soluble form of 4-1BBL is known to occur in humans. Although it is presumably generated by MMP activity, its amino acid size is currently unreported (4). The soluble form is bioactive. Human 4-1BBL signals through both CD137/4-1BB and itself. Its cytoplasmic tail participates in reverse signaling that induces apoptosis in T cells and cytokine secretion (IL-6; TNF-alpha ) by monocytes (7, 8). 4-1BBL binding to CD137/4-1BB produces a number of effects. It seems to play a key role in the T cell recall response. It maintains T cell numbers at the end of a primary response, and induces CD4+ and CD8+ T cells to proliferate and secrete cytokines such as IL-2 and IFN-gamma in CD4+ cells, and IFN-gamma in CD8+ cells (9, 10).
- Kwon, B. et al. (2003) Exp. Mol. Med. 35:8.
- Salih, H.R. et al. (2002) Int. J. Clin. Pharmacol. Ther. 40:348.
- Vinay, D.S. and B.S. Kwon (1998) Semin. Immunol. 1:481.
- Salih, H.R. et al. (2001) J. Immunol. 167:4059.
- Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
- Reali, C. et al. (2003) J. Neurosci. Res. 74:67.
- Michel, J. et al. (1999) Immunology 98:42.
- Langstein, J. et al. (1998) J. Immunol. 160:2488.
- Wen, T. et al. (2002) J. Immunol. 168:4897.
- Dawicki, W. and T.H. Watts (2004) Eur. J. Immunol. 34:743.
Citations for Human 4-1BB Ligand/TNFSF9 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
Authors: J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang
Nature Communications, 2022;13(1):1606.
Sample Types: Cell Lysates
Applications: Western Blot
Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine Atherosclerosis
Authors: C Cochain, E Vafadarnej, P Arampatzi, P Jaroslav, H Winkels, K Ley, D Wolf, AE Saliba, A Zernecke
Circ. Res., 2018;0(0):.
Sample Types: Whole Tissue
Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival.
Authors: Ek S, Bjorck E, Hogerkorp CM, Nordenskjold M, Porwit-MacDonald A, Borrebaeck CA
Int. J. Cancer, 2006;118(8):2092-7.
Sample Types: Whole Tissue
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human 4-1BB Ligand/TNFSF9 Antibody
Average Rating: 4.5 (Based on 2 Reviews)
Have you used Human 4-1BB Ligand/TNFSF9 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Functions well at 2ug/mL.